Insider holders · CIK 0001253689
CRESCENT BIOPHARMA, INC. · CBIO
Every insider with a reported Table I holding at this company, ranked by their last-reported share count. A balance is only as fresh as its filing — the report date sits next to every row on purpose. ← Back to activity
| Insider | Direct shares | Indirect shares | Total reported | Last report (ET) | From |
|---|---|---|---|---|---|
| NEA PARTNERS 10 L P10% Owner | 4,995,664 | — | 4,995,664 | May 11, 2018 · 5:00 pm EDT | Form 4 |
| NEW ENTERPRISE ASSOCIATES 10 L P10% Owner | 4,995,664 | — | 4,995,664 | May 11, 2018 · 5:00 pm EDT | Form 4 |
| Scott D Sandell10% Owner | — | 4,093,377 | 4,093,377 | May 11, 2018 · 5:02 pm EDT | Form 4 |
| M James BarrettDirector | — | 4,093,377 | 4,093,377 | May 11, 2018 · 5:00 pm EDT | Form 4 |
| Peter J Barris10% Owner | — | 4,093,377 | 4,093,377 | May 11, 2018 · 5:01 pm EDT | Form 4 |
| Tomas KiselakDirector | — | 3,601,316 | 3,601,316 | Jul 20, 2026 · 5:30 pm EDT | Form 4 |
| Fairmount Funds Management LLCDirector | — | 3,601,316 | 3,601,316 | Jul 20, 2026 · 5:30 pm EDT | Form 4 |
| Fairmount Healthcare Fund II L.P.Director | — | 3,601,316 | 3,601,316 | Jul 20, 2026 · 5:30 pm EDT | Form 4 |
| Peter Evan HarwinDirector | — | 3,601,316 | 3,601,316 | Jul 20, 2026 · 5:30 pm EDT | Form 4 |
| BVF Partners OS Ltd.relationship not stated | 298,337 | — | 298,337 | May 11, 2017 · 6:55 pm EDT | Form 3 |
| Biotechnology Value Trading Fund OS LPrelationship not stated | 298,337 | — | 298,337 | May 11, 2017 · 6:55 pm EDT | Form 3 |
| Mark N Lampert10% Owner | 298,337 | — | 298,337 | May 11, 2017 · 6:55 pm EDT | Form 3 |
| BIOTECHNOLOGY VALUE FUND II LPrelationship not stated | 298,337 | — | 298,337 | May 11, 2017 · 6:55 pm EDT | Form 3 |
| Inc/il Bvf10% Owner | 298,337 | — | 298,337 | May 11, 2017 · 6:55 pm EDT | Form 3 |
| BVF PARTNERS L P/IL10% Owner | 298,337 | — | 298,337 | May 11, 2017 · 6:55 pm EDT | Form 3 |
| BIOTECHNOLOGY VALUE FUND L Prelationship not stated | 298,337 | — | 298,337 | May 11, 2017 · 6:55 pm EDT | Form 3 |
| Joshua T BrummChief Executive Officer | 271,765 | — | 271,765 | Sep 18, 2026 · 4:02 pm EDT | Form 4 |
| Rachel K. KingPresident, CEO | 140,385 | 45,741 | 186,126 | Feb 14, 2018 · 8:52 am EST | Form 5 |
| Helen M. ThackraySVP Clinical Development, CMO | 148,615 | — | 148,615 | Dec 12, 2017 · 4:14 pm EST | Form 4 |
| Jonathan McNeillPresident and COO | 134,588 | — | 134,588 | Sep 18, 2026 · 4:01 pm EDT | Form 4 |
| John L. MagnaniSVP of Research, CSO | 75,793 | 4,845 | 80,638 | Oct 18, 2018 · 5:36 pm EDT | Form 4 |
| Jan PinkasChief Scientific Officer | 21,581 | — | 21,581 | Sep 18, 2026 · 4:03 pm EDT | Form 4 |
| Ellie Eunkyung ImChief Medical Officer | 21,446 | — | 21,446 | Sep 18, 2026 · 4:02 pm EDT | Form 4 |
| Richard William ScalzoChief Financial Officer | 19,730 | — | 19,730 | Sep 18, 2026 · 4:02 pm EDT | Form 4 |
| Barbara Harlin BisphamSee Remarks | 18,710 | — | 18,710 | Sep 18, 2026 · 4:02 pm EDT | Form 4 |
| Ryan LynchSee Remarks | 13,631 | — | 13,631 | Sep 18, 2026 · 4:03 pm EDT | Form 4 |
| Franklin H Top Jr.Director | 12,294 | — | 12,294 | Feb 12, 2016 · 3:30 pm EST | Form 4 |
| Mark Alan GoldbergDirector | 11,497 | — | 11,497 | Mar 7, 2016 · 8:03 am EST | Form 4 |
| Daniel M JuniusDirector | 8,000 | — | 8,000 | Jun 16, 2017 · 5:14 pm EDT | Form 4 |
| John J. BaldwinDirector | 1,210 | — | 1,210 | Jul 1, 2016 · 11:43 am EDT | Form 4 |
| Brian M. HahnCFO | 0 | — | 0 | Jun 12, 2018 · 5:54 pm EDT | Form 4 |
| Scott KoenigDirector | 0 | — | 0 | Mar 13, 2017 · 4:07 pm EDT | Form 3 |
| Scott Thomas JacksonDirector | 0 | — | 0 | Nov 28, 2018 · 6:59 pm EST | Form 3 |
| Patricia S AndrewsDirector | 0 | — | 0 | Jun 12, 2017 · 4:25 pm EDT | Form 3 |
Balances come from each insider’s most recent filing that reports a Table I holding; an insider who left the company years ago still appears with their last-known figure and its date. Indirect totals collapse multiple vehicles (trusts, LLCs) into one number — open the filing for the breakdown. Shares as filed, not split-adjusted.